$CELG Recent News Two growth stocks that look re
Post# of 89401
Posted On: 12/16/2013 10:40:40 AM
$CELG Recent News
Two growth stocks that look ready to fly 1:29 p.m. Dec. 12, 2013 - The Trading Deck
Nasdaq makes first close above 4,000 in 13 years: stock market live blog recap 5:03 p.m. Nov. 26, 2013 - blogs.marketwatch.com
What the worst advisers are recommending 1:16 p.m. Nov. 21, 2013 - Mark Hulbert
Top performers’ top November bets 11:01 p.m. Nov. 3, 2013 - Mark Hulbert
Celgene raises earnings outlook as sales climb 7:27 a.m. Oct. 24, 2013 - MarketWatch.com
A bull market as typical as any other 11:23 a.m. Oct. 22, 2013 - The Trading Deck
No shortcut to innovation 7:30 a.m. Oct. 2, 2013 - Mark Hulbert
Market uptrend bends, without cracking 11:55 a.m. Oct. 1, 2013 - Michael Ashbaugh
Market technicals bend, without cracking 11:38 a.m. Oct. 1, 2013 - Michael Ashbaugh
Of keg parties and Big Ben 11:29 a.m. Sept. 19, 2013 - The Trading Deck
Updates, advisories and surprises 4:31 p.m. July 25, 2013 - MarketWatch
Tech ETF QQQ gains on Facebook, other earnings 8:48 a.m. July 25, 2013 - Victor Reklaitis
Celgene profit up 30% as Revlimid sales increase 6:55 a.m. July 25, 2013 - MarketWatch.com
4 things traders should know for the next 24 hours 5:37 p.m. July 24, 2013 - blogs.marketwatch.com
The Next 24: Internet Stocks Jump 3:39 p.m. July 24, 2013 - MarketWatch
Charting a slow-motion rally to record territory 11:06 a.m. July 23, 2013 - Michael Ashbaugh
Charting a slow-motion rally to record territory 10:50 a.m. July 23, 2013 - Michael Ashbaugh
Thursday’s movers: Microsoft rallies on revamp 3:44 p.m. July 11, 2013 - Sue Chang
Celgene's study data may boost cancer drug sales 1:37 p.m. July 11, 2013 - MarketWatch.com
Celgene shares surge on test results from cancer treatment 10:36 a.m. July 11, 2013 - Russ Britt
What To Buy: Celgene Corporation's Buy Recommendation Reiterated 9:00 a.m. Today - TheStreet.com
How big pharma sells A.D.H.D 5:13 p.m. Dec. 15, 2013 - Seeking Alpha
Ziopharm: Finally A Winner In The War On Cancer? 1:22 p.m. Dec. 15, 2013 - Seeking Alpha
2013 Top Stocks Netflix, Micron May Not Do as Well in 2014 10:55 a.m. Dec. 13, 2013 - TheStreet.com
Celgene, Agios Extend Tie-up - Analyst Blog 11:30 a.m. Dec. 12, 2013 - Zacks.com
3 Large Cap Healthcare Stocks That Belong in Your Portfolio 9:23 a.m. Dec. 12, 2013 - Wall St. Cheat Sheet
Follow The Money 5:23 a.m. Dec. 12, 2013 - Seeking Alpha
Spread the Love With CELG Stock Options 3:20 a.m. Dec. 12, 2013 - InvestorPlace.com
Novartis: 2 Novel Cancer Therapies Show Promising Results 2:13 p.m. Dec. 11, 2013 - Seeking Alpha
Celgene, Agios extend cancer collaboration 2:12 p.m. Dec. 11, 2013 - Seeking Alpha
Celgene And The Chronic Disease Fund: The Next Domino To Fall? 12:08 p.m. Dec. 11, 2013 - Seeking Alpha
Will Biotech Outperform Again in 2014? 10:47 a.m. Dec. 11, 2013 - Barrons.com
Biotech Stock Roundup: GILD Scores FDA Approval, Ambit Plunges - Analyst Blog 10:41 a.m. Dec. 11, 2013 - Zacks.com
The Best Biotech CEO of 2013 is... 10:01 a.m. Dec. 11, 2013 - TheStreet.com
The One True Sector Bubble: Profits Here When It Crashes Soon 9:17 a.m. Dec. 11, 2013 - benzinga.com
Credit Suisse Offers Top Biotech Stocks to Buy for 2014 8:10 a.m. Dec. 11, 2013 - 247WallSt.com
Did The Government Shutdown Help The Economy? 6:39 p.m. Dec. 10, 2013 - Seeking Alpha
Celgene Rises on Positive Revlimid Data - Analyst Blog 5:20 p.m. Dec. 10, 2013 - Zacks.com
Jim Cramer's 6 Stocks in 60 Seconds: FDX PVH TWTR BURL CELG PF (Update 1) 5:10 p.m. Dec. 10, 2013 - TheStreet.com
Newly Transformed Nuvilex To Enjoy Strong 2014 11:33 a.m. Dec. 10, 2013 - Seeking Alpha
Agios Advances Cancer Metabolism Collaboration with Celgene 8:16 a.m. Dec. 11, 2013 - BusinessWire
Studies Evaluating REVLIMID(R) (Lenalidomide) in Lymphoma Presented at ASH 7:00 p.m. Dec. 10, 2013 - BusinessWire
Two Studies Highlight Retrospective Analyses of Phase III Study of POMALYST(R)/IMNOVID(R) (Pomalidomide) in Previously Treated Multiple Myeloma Patients Presented at ASH 8:30 a.m. Dec. 10, 2013 - BusinessWire
REVLIMID(R) (lenalidomide)-Treated Patients with Deletion-5q MDS Who Achieve Transfusion-Independence of At Least 26 Weeks and AML-Free Survival Associated with Cytogenetic Response 7:30 p.m. Dec. 9, 2013 - BusinessWire
Stock Price Movements, Completed Acquisitions, and New Clinical Studies - Research Report on UnitedHealth Group, Mylan, St. Jude Medical, and Cigna 8:00 a.m. Dec. 9, 2013 - PR Newswire
First Analysis of Extended Dosing with Celgene Epigenetic Agent CC-486 in Patients with Higher-Risk Myelodysplastic Syndromes Presented at ASH 9:37 p.m. Dec. 7, 2013 - BusinessWire
Biotech Briefing: Advancing Biotechs Forging Ahead With Breaking News Developments: Alliqua, OncoMed Pharmaceuticals, EnteroMedics, Unilife, Amarin 9:05 a.m. Dec. 4, 2013 - PR Newswire
OncoMed and Celgene Announce Strategic Collaboration Advancing Multiple Anti-Cancer Stem Cell Therapeutics to Offer Potential Benefits to Cancer Patients 7:30 a.m. Dec. 3, 2013 - GlobeNewswire
Positive Opinion, Stock Price Movement, and Executive Appointments - Research Report on Celgene, Sirona, Centene, Fresenius Medical Care, and PerkinElmer 8:00 a.m. Nov. 28, 2013 - PR Newswire
Critical Alerts For American Express, Celgene, Altera, JC Penney, and Coach Released By InvestorsObserver 9:31 a.m. Nov. 25, 2013 - PR Newswire
Today's Research: Celgene Corp., Forest Laboratories Inc., Edwards Lifesciences Corp., and Peregrine Pharma Inc. 1:30 p.m. Nov. 22, 2013 - PR Newswire
Celgene Receives Positive CHMP Opinion for ABRAXANE(R) in Combination with Gemcitabine as Treatment for Patients with Metastatic Pancreatic Cancer 7:25 a.m. Nov. 22, 2013 - BusinessWire
FDA Approvals, Stock Price Movements, and Study Results - Research Report on Pfizer, Celgene, Merck, Quest Diagnostics, and Pharmacyclics 8:00 a.m. Nov. 21, 2013 - PR Newswire
Alliqua Announces Transaction with Celgene 7:30 a.m. Nov. 19, 2013 - BusinessWire
Acquisitions, Quarterly Reports, and Stock Price Movements - Research Report on Santarus, Celgene, Pharmacyclics, Quest Diagnostics, and Stryker 8:00 a.m. Nov. 13, 2013 - PR Newswire
Initial Phase III Results of the FIRST(R) Trial (MM-020/IFM 07 01) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (PTS) Ineligible for Stem Cell Transplantation (SCT) Accepted for Plenary Presentation at ASH Annual Meeting 9:02 a.m. Nov. 7, 2013 - BusinessWire
Positive Clinical Data, Upcoming Presentations, and Completed Acquisitions - Research Report on Merck, Perrigo, Celgene, Cigna, and Boston Scientific 8:00 a.m. Nov. 6, 2013 - PR Newswire
Pre-Market Review: Celgene Corp., Forest Laboratories Inc., Peregrine Pharma Inc., and Edwards Lifesciences Corp. 4:03 p.m. Oct. 31, 2013 - PR Newswire
Healthcare Companies Report Quarterly Financial Results - Research Report on Celgene, Natus, Merit Medical, Invacare, and Zalicus 9:00 a.m. Oct. 30, 2013 - PR Newswire
Celgene Corporation to Webcast at Upcoming Investor Conferences and Medical Congress 8:30 a.m. Oct. 30, 2013 - BusinessWire
Two growth stocks that look ready to fly 1:29 p.m. Dec. 12, 2013 - The Trading Deck
Nasdaq makes first close above 4,000 in 13 years: stock market live blog recap 5:03 p.m. Nov. 26, 2013 - blogs.marketwatch.com
What the worst advisers are recommending 1:16 p.m. Nov. 21, 2013 - Mark Hulbert
Top performers’ top November bets 11:01 p.m. Nov. 3, 2013 - Mark Hulbert
Celgene raises earnings outlook as sales climb 7:27 a.m. Oct. 24, 2013 - MarketWatch.com
A bull market as typical as any other 11:23 a.m. Oct. 22, 2013 - The Trading Deck
No shortcut to innovation 7:30 a.m. Oct. 2, 2013 - Mark Hulbert
Market uptrend bends, without cracking 11:55 a.m. Oct. 1, 2013 - Michael Ashbaugh
Market technicals bend, without cracking 11:38 a.m. Oct. 1, 2013 - Michael Ashbaugh
Of keg parties and Big Ben 11:29 a.m. Sept. 19, 2013 - The Trading Deck
Updates, advisories and surprises 4:31 p.m. July 25, 2013 - MarketWatch
Tech ETF QQQ gains on Facebook, other earnings 8:48 a.m. July 25, 2013 - Victor Reklaitis
Celgene profit up 30% as Revlimid sales increase 6:55 a.m. July 25, 2013 - MarketWatch.com
4 things traders should know for the next 24 hours 5:37 p.m. July 24, 2013 - blogs.marketwatch.com
The Next 24: Internet Stocks Jump 3:39 p.m. July 24, 2013 - MarketWatch
Charting a slow-motion rally to record territory 11:06 a.m. July 23, 2013 - Michael Ashbaugh
Charting a slow-motion rally to record territory 10:50 a.m. July 23, 2013 - Michael Ashbaugh
Thursday’s movers: Microsoft rallies on revamp 3:44 p.m. July 11, 2013 - Sue Chang
Celgene's study data may boost cancer drug sales 1:37 p.m. July 11, 2013 - MarketWatch.com
Celgene shares surge on test results from cancer treatment 10:36 a.m. July 11, 2013 - Russ Britt
What To Buy: Celgene Corporation's Buy Recommendation Reiterated 9:00 a.m. Today - TheStreet.com
How big pharma sells A.D.H.D 5:13 p.m. Dec. 15, 2013 - Seeking Alpha
Ziopharm: Finally A Winner In The War On Cancer? 1:22 p.m. Dec. 15, 2013 - Seeking Alpha
2013 Top Stocks Netflix, Micron May Not Do as Well in 2014 10:55 a.m. Dec. 13, 2013 - TheStreet.com
Celgene, Agios Extend Tie-up - Analyst Blog 11:30 a.m. Dec. 12, 2013 - Zacks.com
3 Large Cap Healthcare Stocks That Belong in Your Portfolio 9:23 a.m. Dec. 12, 2013 - Wall St. Cheat Sheet
Follow The Money 5:23 a.m. Dec. 12, 2013 - Seeking Alpha
Spread the Love With CELG Stock Options 3:20 a.m. Dec. 12, 2013 - InvestorPlace.com
Novartis: 2 Novel Cancer Therapies Show Promising Results 2:13 p.m. Dec. 11, 2013 - Seeking Alpha
Celgene, Agios extend cancer collaboration 2:12 p.m. Dec. 11, 2013 - Seeking Alpha
Celgene And The Chronic Disease Fund: The Next Domino To Fall? 12:08 p.m. Dec. 11, 2013 - Seeking Alpha
Will Biotech Outperform Again in 2014? 10:47 a.m. Dec. 11, 2013 - Barrons.com
Biotech Stock Roundup: GILD Scores FDA Approval, Ambit Plunges - Analyst Blog 10:41 a.m. Dec. 11, 2013 - Zacks.com
The Best Biotech CEO of 2013 is... 10:01 a.m. Dec. 11, 2013 - TheStreet.com
The One True Sector Bubble: Profits Here When It Crashes Soon 9:17 a.m. Dec. 11, 2013 - benzinga.com
Credit Suisse Offers Top Biotech Stocks to Buy for 2014 8:10 a.m. Dec. 11, 2013 - 247WallSt.com
Did The Government Shutdown Help The Economy? 6:39 p.m. Dec. 10, 2013 - Seeking Alpha
Celgene Rises on Positive Revlimid Data - Analyst Blog 5:20 p.m. Dec. 10, 2013 - Zacks.com
Jim Cramer's 6 Stocks in 60 Seconds: FDX PVH TWTR BURL CELG PF (Update 1) 5:10 p.m. Dec. 10, 2013 - TheStreet.com
Newly Transformed Nuvilex To Enjoy Strong 2014 11:33 a.m. Dec. 10, 2013 - Seeking Alpha
Agios Advances Cancer Metabolism Collaboration with Celgene 8:16 a.m. Dec. 11, 2013 - BusinessWire
Studies Evaluating REVLIMID(R) (Lenalidomide) in Lymphoma Presented at ASH 7:00 p.m. Dec. 10, 2013 - BusinessWire
Two Studies Highlight Retrospective Analyses of Phase III Study of POMALYST(R)/IMNOVID(R) (Pomalidomide) in Previously Treated Multiple Myeloma Patients Presented at ASH 8:30 a.m. Dec. 10, 2013 - BusinessWire
REVLIMID(R) (lenalidomide)-Treated Patients with Deletion-5q MDS Who Achieve Transfusion-Independence of At Least 26 Weeks and AML-Free Survival Associated with Cytogenetic Response 7:30 p.m. Dec. 9, 2013 - BusinessWire
Stock Price Movements, Completed Acquisitions, and New Clinical Studies - Research Report on UnitedHealth Group, Mylan, St. Jude Medical, and Cigna 8:00 a.m. Dec. 9, 2013 - PR Newswire
First Analysis of Extended Dosing with Celgene Epigenetic Agent CC-486 in Patients with Higher-Risk Myelodysplastic Syndromes Presented at ASH 9:37 p.m. Dec. 7, 2013 - BusinessWire
Biotech Briefing: Advancing Biotechs Forging Ahead With Breaking News Developments: Alliqua, OncoMed Pharmaceuticals, EnteroMedics, Unilife, Amarin 9:05 a.m. Dec. 4, 2013 - PR Newswire
OncoMed and Celgene Announce Strategic Collaboration Advancing Multiple Anti-Cancer Stem Cell Therapeutics to Offer Potential Benefits to Cancer Patients 7:30 a.m. Dec. 3, 2013 - GlobeNewswire
Positive Opinion, Stock Price Movement, and Executive Appointments - Research Report on Celgene, Sirona, Centene, Fresenius Medical Care, and PerkinElmer 8:00 a.m. Nov. 28, 2013 - PR Newswire
Critical Alerts For American Express, Celgene, Altera, JC Penney, and Coach Released By InvestorsObserver 9:31 a.m. Nov. 25, 2013 - PR Newswire
Today's Research: Celgene Corp., Forest Laboratories Inc., Edwards Lifesciences Corp., and Peregrine Pharma Inc. 1:30 p.m. Nov. 22, 2013 - PR Newswire
Celgene Receives Positive CHMP Opinion for ABRAXANE(R) in Combination with Gemcitabine as Treatment for Patients with Metastatic Pancreatic Cancer 7:25 a.m. Nov. 22, 2013 - BusinessWire
FDA Approvals, Stock Price Movements, and Study Results - Research Report on Pfizer, Celgene, Merck, Quest Diagnostics, and Pharmacyclics 8:00 a.m. Nov. 21, 2013 - PR Newswire
Alliqua Announces Transaction with Celgene 7:30 a.m. Nov. 19, 2013 - BusinessWire
Acquisitions, Quarterly Reports, and Stock Price Movements - Research Report on Santarus, Celgene, Pharmacyclics, Quest Diagnostics, and Stryker 8:00 a.m. Nov. 13, 2013 - PR Newswire
Initial Phase III Results of the FIRST(R) Trial (MM-020/IFM 07 01) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (PTS) Ineligible for Stem Cell Transplantation (SCT) Accepted for Plenary Presentation at ASH Annual Meeting 9:02 a.m. Nov. 7, 2013 - BusinessWire
Positive Clinical Data, Upcoming Presentations, and Completed Acquisitions - Research Report on Merck, Perrigo, Celgene, Cigna, and Boston Scientific 8:00 a.m. Nov. 6, 2013 - PR Newswire
Pre-Market Review: Celgene Corp., Forest Laboratories Inc., Peregrine Pharma Inc., and Edwards Lifesciences Corp. 4:03 p.m. Oct. 31, 2013 - PR Newswire
Healthcare Companies Report Quarterly Financial Results - Research Report on Celgene, Natus, Merit Medical, Invacare, and Zalicus 9:00 a.m. Oct. 30, 2013 - PR Newswire
Celgene Corporation to Webcast at Upcoming Investor Conferences and Medical Congress 8:30 a.m. Oct. 30, 2013 - BusinessWire
(0)
(0)